Clinical trials: Nephropathy
Chronic Peritoneal Dialysis
Method of Exit Site Care in Chronic Peritoneal Dialysis Patients
Peritoneal dialysis accounts for more than 70% of the dialysis modality in Hong Kong. Exit site infection (ESI) is one of the causes leading to peritoneal catheter removal. Appropriate exit-site care can prevent ESI.
- Trial name
- NCT00416338
- Testing
- film dressing by adhesive
- Where
- Hong Kong
- Volunteers
- 11 people
- Sponsor
- Chinese University of Hong Kong
Kidney Disease, Kidney Transplantation
BIOmarkers Before and After Kidney Transplantation
In clinical nephrology, the search for urinary, blood and tissue biomarkers of specific kidney diseases is an important goal. In recent years, the use of these biomarkers has made it possible to diagnose many renal diseases that…
- Trial name
- PROBIOT (NCT06810258)
- Testing
- Blood sample during native kidney biopsy, Blood sample during renal graft biopsy, Urine sample during renal graft biopsy
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chemotherapy Side Effects, Machine Learning
Prospective Validation of Machine Learning Model to Predict Platinum Induced Nephrotoxicity in Cancer Patients
This study aims to investigate the utility of predictive models for chemotherapy-induced nephrotoxicity in the Taiwanese cancer population.
- Conditions
- Chemotherapy Side Effects, Machine Learning, Acute Kidney Injury, Acute Kidney Disease
- Trial name
- NCT07114276
- Testing
- Machine learning models predictions of acute kidney injury and acute kidney disease
- Where
- Taiwan
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
Dialysis, Chronic Renal Failure
A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System
The study objective is to verify the safety and effectiveness of the DBB-EXA ES Hemodialysis Delivery System to consistently deliver dialysate of the appropriate quality for infusion.
- Trial name
- HEMO (NCT04655989)
- Testing
- DBB-EXA ES Hemodialysis System
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Nikkiso America, Inc.
Autosomal Dominant Polycystic Kidney Disease, Hypertension
Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
A randomized, open-label single-center study investigates the efficacy and safety of bilateral renal artery sympathetic denervation by catheter-based radiofrequency ablation on blood pressure and disease progression control in…
- Trial name
- RAFALE (NCT01932450)
- Testing
- renal sympathetic denervation, antihypertensive drugs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Mei changlin
Renal Neoplasms, Targeted Molecular Therapy
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate.
- Trial name
- NCT02688491
- Testing
- sunitinib
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Chronic Kidney Diseases, Haemodialysis
Live Classical Music and the Response to the Disease and Its Evolution in Patients With Chronic Renal Failure
People are most vulnerable to anxiety when faced with life-threatening situations such as illness, medical treatments and surgeries.
- Trial name
- NCT05729997
- Testing
- Listening to live classical music
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Hospital Universitario La Fe
Renal Cell Carcinoma
Neoadjuvant Pazopanib in Renal Cell Carcinoma
This study will be a single arm phase II clinical trial of 8 weeks of daily, oral neo-adjuvant pazopanib prior to nephrectomy in 39 evaluable patients with histologically confirmed localized renal cell carcinoma (RCC).
- Trial name
- NCT01361113
- Testing
- Pazopanib
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
End-Stage Renal Disease, Kidney Transplantation
A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant
The purpose of this study is to compare treatment with the new drug sirolimus (SRL) versus the standard treatment with cyclosporine (CsA) or tacrolimus in children who have received kidney transplants.
- Trial name
- NCT00005113
- Testing
- Cyclosporine, Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Boston Children's Hospital
Endothelial Dysfunction, End-Stage Renal Disease
Ramipril vs. Amlodipine in Pediatric Hemodialysis Patients
The goal of this clinical trial is to learn if Ramipril works better than Amlodipine to reduce endothelial dysfunction in pediatric patients (aged 5-18 years) with end-stage kidney disease undergoing maintenance hemodialysis and…
- Conditions
- Endothelial Dysfunction, End-Stage Renal Disease, Pediatric Kidney Disease
- Trial name
- ADMA /PedsQL (NCT07879560)
- Testing
- Ramipril tablet, Amlodipine tablet
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Chronic Renal Failure, Chronic Kidney Disease
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen), based on maintenance of hemoglobin (Hb) levels and study drug dose requirements in patients…
- Trial name
- AiME - 13 (NCT01473420)
- Testing
- Epoetin Hospira, Epogen Amgen
- Where
- 73 sites in United States
- Volunteers
- 320 people
- Sponsor
- Pfizer
Chronic Renal Failure, Hemodialysis
Effects of Shenkang Decoction on Creatinine and Blood Urea Nitrogen in Chronic Renal Failure Hemodialysis Patients
To explore the clinical effect of Shenkang Decoction in chronic renal failure (CRF) patients with hemodialysis (HD).
- Trial name
- NCT05631782
- Testing
- Shenkang decoction
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The First People's Hospital of Zunyi
Renal Insufficiency, End Stage Renal Disease
A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT03482024
- Testing
- Tirzepatide
- Where
- 4 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Aortic Aneurysm, Abdominal, Renal Insufficiency
Renal Function After Stentgraft Treatment Of Abdominal Aortic Aneurysm
This randomized controlled trial aim to determine the impact on renal function after treatment for infrarenal abdominal aortic aneurysm (AAA) with stentgrafts either with active supra- or infrarenal fixation.
- Conditions
- Aortic Aneurysm, Abdominal, Renal Insufficiency, Stent-Graft Thrombosis
- Trial name
- RENOFIX (NCT04754659)
- Testing
- Stentgraft
- Where
- Sweden
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Septic Shock
Changes in Microvascular Perfusion During Blood Purification With Cytosorb® in Septic Shock
Sepsis is defined as a life-threatening event due to a dysregulated immune response to an host. Blood purification techniques may be considered as a therapeutic weapon to front sepsis and septic shock.
- Trial name
- NCT03456180
- Testing
- Haemoadsorption with Cytosorb cartridge
- Volunteers
- 10 people
- Sponsor
- Università Politecnica delle Marche
Kidney Diseases
YSPSL for Prevention of Delayed Graft Function Part B
Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced kidney injury and resultant delayed graft function (DGF). PSGL-1 is a ligand for P-, E-, and L-selectin.
- Trial name
- NCT00298168
- Testing
- YSPSL
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Y's Therapeutics, Inc.
Primary IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
The purpose of this study is to evaluate the efficacy, safety, \& pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high…
- Trial name
- IMAGINATION (NCT05797610)
- Testing
- Sefaxersen (RO7434656)
- Where
- 171 sites in United States, Argentina and 19 more
- Volunteers
- 459 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma (RCC), Radioembolization
Ablative Radioembolization of Renal Cell Carcinoma Trial
Renal cell carcinoma (RCC), the most common type of kidney cancer, is typically treated with surgery; however, there is no established therapy for patients who are not surgical candidates and who have tumours greater than 4.0 cm…
- Trial name
- ARRCC (NCT06642220)
- Testing
- Y-90 Selective Internal Radiation Therapy (SIRT)
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Derek W. Cool
Diabetic Nephropathy
Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD
Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality.
- Trial name
- NXT-DKD (NCT07698223)
- Testing
- Naoxintong Capsule
- Where
- 8 sites in China
- Volunteers
- 410 people
- Sponsor
- Chen Xiangmei
Chronic Disease, Kidney Diseases
Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?
Peritoneal dialysis patients are at increased risk of cardiovascular morbidity and mortality and are related to the presence of accelerated atherosclerosis.
- Conditions
- Chronic Disease, Kidney Diseases, Cardiovascular Diseases
- Trial name
- NCT00516880
- Testing
- rosiglitazone
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Hospital Authority, Hong Kong